Association Between Change in Ambulatory Hemodynamic Pressures and Symptoms of Heart Failure

Circ Heart Fail. 2021 Nov;14(11):e008446. doi: 10.1161/CIRCHEARTFAILURE.121.008446. Epub 2021 Oct 26.

Michael E Nassif^{1

2}, John A Spertus^{1

2}, Fengming Tang¹, Sheryl L Windsor¹, Philip Jones¹, Merrill Thomas^{1

2}, Yevgeniy Khariton^{1

2}, John Brush^{3

4}, Robert A Gordon⁵, Rita Jermyn⁶, Orvar Jonsson⁷, Sumant Lamba⁸, David M Shavelle⁹, Mikhail N Kosiborod^{1

2

10

11}

¹ Saint Luke's Mid America Heart Institute, Kansas City, MO (M.E.N., J.A.S., F.T., S.L.W., P.J., M.T., Y.K., M.N.K.).
² University of Missouri-Kansas City (M.E.N., J.A.S., M.T., Y.K., M.N.K.).
³ Sentara Healthcare, Norfolk, VA (J.B.).
⁴ Eastern Virginia Medical School, Norfolk, VA (J.B.).
⁵ NorthShore University HealthSystem, Evanston, IL (R.A.G.).
⁶ St. Francis, Roslyn, NY (R.J.).
⁷ University of South Dakota Sanford Health, Sioux Falls (O.J.).
⁸ First Coast Cardiovascular Institute, Jacksonville, FL (S.L.).
⁹ University of Southern California, Los Angeles (D.M.S.).
¹⁰ The George Institute for Global Health, Sydney, Australia (M.N.K.).
¹¹ University of New South Wales, Sydney, Australia (M.N.K.).

No abstract available

Keywords: empagliflozin; health status; heart failure; pulmonary artery; quality of life.

Publication types